Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mycophenolate mofetil.

Jeffrey Zwerner1, David Fiorentino

  • 1Department of Dermatology, Stanford University, Palo Alto, California, USA.

Dermatologic Therapy
|November 1, 2007
PubMed
Summary
This summary is machine-generated.

Mycophenolate mofetil (MMF) is an effective immunosuppressant for inflammatory skin diseases. Its favorable safety profile, with no liver or kidney toxicity, makes it a valuable option in dermatology.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial Intelligence-Aided Lung Ultrasound Detection of Interstitial Lung Disease in Systemic Sclerosis and Inflammatory Myopathy.

Arthritis care & research·2026
Same author

A Phase 3 Trial of Brepocitinib in Dermatomyositis.

The New England journal of medicine·2026
Same author

Autoantibodies as biomarkers of cancer risk in dermatomyositis.

JID innovations : skin science from molecules to population health·2026
Same author

RNA origin of sex-biased immunity.

Molecular therapy. Nucleic acids·2026
Same author

Identification of Adult Patients With Dermatomyositis Using Real-World Data Sources.

Arthritis care & research·2025
Same author

Risk of head and neck cancer in dermatomyositis: Findings from a retrospective US-based cohort study.

Journal of the American Academy of Dermatology·2025
Same journal

Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis.

Dermatologic therapy·2024
Same journal

Correction to "Adjuvant PD-1 inhibitor versus high-dose interferon α-2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis".

Dermatologic therapy·2022
Same journal

A case of erythema nodosum concomitant with ulcerative colitis relieved by tofacitinib.

Dermatologic therapy·2022
Same journal

A case report of vitiligo following toripalimab therapy for a patient with metastatic melanoma.

Dermatologic therapy·2022
Same journal

High versus low dose oral isotretinoin in the treatment of cutaneous and genital warts.

Dermatologic therapy·2022
Same journal

Evaluation of the efficacy and relapse rates of treatment protocols for moderate acne using isotretinoin based on the global acne grading system: Randomized, controlled, comparative study.

Dermatologic therapy·2022
See all related articles

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Mycophenolate mofetil (MMF) is an immunosuppressive agent increasingly used in dermatology.
  • Initially developed for psoriasis treatment, MMF shows efficacy in various inflammatory skin conditions.

Purpose of the Study:

  • To review the pharmacology, mechanism of action, side effects, and dermatologic applications of MMF.
  • To provide practical guidance on MMF usage based on literature and clinical experience.

Main Methods:

  • Literature review of MMF in dermatologic conditions.
  • Analysis of safety data from organ transplantation and dermatology.

Main Results:

  • MMF demonstrates efficacy in treating inflammatory skin diseases.

Related Experiment Videos

  • MMF possesses a favorable safety profile, notably lacking hepatic or renal toxicity, unlike other dermatologic immunosuppressants.

    • Conclusions:

    • MMF is a promising immunosuppressive agent for dermatologic use due to its efficacy and safety.
    • Its lack of organ toxicity makes it suitable for combination therapy in managing complex skin conditions.